$SRRK

Reed Joshua sold $164K of SRRK

Reed Joshua sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.74 ($53.50–$54.28, $0.16M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reed Joshua
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure provides transparency on insider selling activity but does not include new company performance, guidance, or deal information.

02

Market read

Traders may monitor SRRK for broader insider activity, but this specific Form 4 is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article does not disclose any concurrent buy/sell by other insiders, changes in guidance, or new company events that would contextualize the sale.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-06 for trades dated 2026-07-01

Background

The article summarizes an SEC Form 4 insider transaction by a director of Scholar Rock Holding Corp.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Scholar Rock Holding director Reed Joshua sold about 3,053 shares in open-market transactions totaling $164,067.43 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal sector read-through; this is company-specific insider activity without disclosed operational or regulatory changes.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so traders may ignore it.

Key entities

  • Scholar Rock Holding Corp

    US-listed company whose director filed an SEC Form 4 for open-market share sales under a 10b5-1 plan.

  • Reed Joshua

    Director who sold 3,053 shares totaling $164,067.43 across two trades dated 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

$SRRKHighAI 9/10

Scholar Rock wins FDA approval for spinal muscle atrophy drug

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.